Oragenics Inc. Form 8-K Summary
Business Context and Reporting Period
Oragenics Inc. filed this Current Report on Form 8-K on May 10, 2017, to disclose the entry into material definitive agreements and the creation of direct financial obligations. The company is a biopharmaceutical entity focused on developing treatments for oral mucositis.
Key Financial Metrics and Transactions
- Preferred Stock Financing: Entered into a securities purchase agreement to raise up to $3.0 million in Series A Convertible Preferred Stock.
- Cash Proceeds: Received approximately $1.302 million at the first closing on May 10, 2017. A second closing for the remaining $1.698 million is contingent upon shareholder approval.
- Debt Financing: Issued a $2.4 million unsecured non-convertible promissory note to Intrexon Corporation (the "Intrexon Note").
- Debt Terms: The Intrexon Note carries a 12% simple interest rate per annum and matures in two years.
- Equity Dilution: The $3.0 million Preferred Stock converts into 12 million shares of Common Stock at a fixed price of $0.25 per share. Warrants were issued to purchase 4,621,037 shares at the first closing, with an additional 6,024,124 warrants to be issued at the second closing (exercise price $0.31 per share).
Material Changes and Agreements
- Intrexon Collaboration Amendment: Amended the Exclusive Channel Collaboration Agreement (ECC) with Intrexon. The first milestone payment was increased from $2.0 million (upon first dosing) to $3.0 million.
- Milestone Trigger: The new $3.0 million milestone is payable upon the earlier of (a) dosing of the last patient in a Phase II clinical trial or (b) the 24-month anniversary of the first patient dosing in the Phase II trial.
- Use of Proceeds: Preferred Stock proceeds are designated for general corporate purposes and working capital. Intrexon Note proceeds are specifically for AG013 research and clinical trials.
Outlook, Risks, and Contingencies
- Contingency: The second closing of the Preferred Stock Financing ($1.698 million) is contingent upon receiving shareholder approval required by NYSE MKT listing rules.
- Shareholder Support: The Company has secured voting agreements with the Koski Family Limited Partnership and Intrexon Corporation, who hold a majority of common stock, to vote in favor of the required approval.
- Liquidity: The transactions are intended to provide immediate working capital and fund specific clinical trial milestones.
- Unregistered Securities: The Preferred Stock, Note, and Warrants were sold in reliance on exemptions from registration under Section 4(2) and Regulation D of the Securities Act of 1933.
Investor Verification Checklist
- Verify the status of the shareholder vote required to close the second tranche of the $3.0 million Preferred Stock financing.
- Confirm the specific terms of the Intrexon Note, including the 12% interest rate and 2-year maturity.
- Review the amended ECC milestone triggers to understand the timing of the potential $3.0 million payment obligation.
- Assess the dilution impact of the 12 million convertible shares and approximately 10.6 million warrant shares.
- Examine the attached exhibits (10.1, 10.3, 4.2) for full legal terms of the financing agreements.